证券代码：000953 证券简称：河化股份 公告编号：2025-027 广西河池化工股份有限公司 关于筹划控制权变更事项进展暨继续停牌的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和 完整，没有虚假记载、误导性陈述或者重大遗漏。 特别提示： 1、广西河池化工股份有限公司（以下简称"公司"）股票（股票 简称：河化股份，股票代码：000953）自2025年8月4日（星期一）上午 开市起继续停牌，预计停牌时间不超过3个交易日。 2、本次公司控制权变更事项目前处于商谈阶段，结果尚存在不确 定性，敬请广大投资者关注后续公告，注意投资风险。 一、停牌事项 2025年7月30日，公司收到控股股东宁波银亿控股有限公司（以下 简称"银亿控股"）的通知，其正在筹划转让其所持有的公司 23.76% 的股权事宜，该事项可能导致公司控制权发生变更。目前各方尚未签 署相关正式交易协议，正就相关事项进行进一步论证和磋商，具体情 况以各方签订的相关正式交易协议为准。 鉴于该事项正在筹划中，尚未签署协议，具有较大不确定性。为 保证公平信息披露，维护投资者利益，避免公司股价异常波动，经公 司向深圳证券交易所申请，公司股票（股票简称： ...

专题：专题|2024年度A股董秘数据报告：1144位董秘年薪超百万 占比超21% 从薪酬分布看，A股原料药上市公司董秘年薪平均值为60.84万元。经统计，处于50万以下、50万-100万、100万以上各区间的人数分别为23人、19人、5人，占比分别为49%、40%、11%。 其中，年薪排行前五的董秘分别为国邦医药的龚裕达、赛分科技的王中蕾、科源制药的李春桦、奥锐特的李芳芳、浙江医药的邵旻之。其年薪分别为193.09万元、151.4万元、120万元、117 年薪不足20万的董秘共三人，分别为新天地的谢雨珊、东亚药业的周剑波、欧康医药的曹永强，三人2024年年薪分别为17.42万元、18.75万元、19.07万元。从任职年限看，三位薪酬最低董 从接待投资者次数看，各上市公司接待情况差异较大。经统计，年接待次数小于10次的公司数量为20家，占比43%；接待次数为10次-100次的公司数量为19家，占比40%；接待次数为100次-3 其中，接待投资者次数0次的公司共5家，分别为奥翔药业、川宁生物、新赣江、峆一药业、新天地。 5家年接待投资者次数最多的公司分别为黄山胶囊、河化股份、博瑞医药（维权）、威尔药业、美诺华（维 ...

专题：专题|2024年度A股董秘数据报告：1144位董秘年薪超百万 占比超21% 董秘作为连接投资者与上市公司的"桥梁"，在上市公司资本运作中发挥着关键作用。新浪财经《2024年 度A股董秘数据报告》显示，2024年A股上市公司董秘薪酬合计达40.86亿元，平均年薪75.43万元。 分行业来看，统计数据显示，A股共有47家上市原料药公司，董事会秘书聘任总体情况如下（部分统计 口径剔除无效数据）。 从董秘的年龄分布来看，介于30-50岁的董秘是市场的中坚力量，占比共计达到60%；50岁以上的董秘 占比为38%；小于等于30岁的董秘群体占比为2%。其中，最年轻的上市公司董秘年仅30岁，为赛分科 技的王中蕾。 年薪不足20万的董秘共三人，分别为新天地的谢雨珊、东亚药业的周剑波、欧康医药的曹永强，三人 2024年年薪分别为17.42万元、18.75万元、19.07万元。从任职年限看，三位薪酬最低董秘均为近两年任 职。 从接待投资者次数看，各上市公司接待情况差异较大。经统计，年接待次数小于10次的公司数量为20 家，占比43%；接待次数为10次-100次的公司数量为19家，占比40%；接待次数为100次-300次的公司 ...

专题：专题|2024年度A股董秘数据报告：1144位董秘年薪超百万 占比超21% 从薪酬分布看，A股原料药上市公司董秘年薪平均值为60.84万元。经统计，处于50万以下、50万-100 万、100万以上各区间的人数分别为23人、19人、5人，占比分别为49%、40%、11%。 其中，年薪排行前五的董秘分别为国邦医药的龚裕达、赛分科技的王中蕾、科源制药的李春桦、奥锐特 的李芳芳、浙江医药的邵旻之。其年薪分别为193.09万元、151.4万元、120万元、117.6万元和108.32万 元。从任职年限看，五位最高薪董秘分别于公司任职5年、不足1年、5年、8年、不足2年。 年薪不足20万的董秘共三人，分别为新天地的谢雨珊、东亚药业的周剑波、欧康医药的曹永强，三人 2024年年薪分别为17.42万元、18.75万元、19.07万元。从任职年限看，三位薪酬最低董秘均为近两年任 职。 董秘作为连接投资者与上市公司的"桥梁"，在上市公司资本运作中发挥着关键作用。新浪财经《2024年 度A股董秘数据报告》显示，2024年A股上市公司董秘薪酬合计达40.86亿元，平均年薪75.43万元。 分行业来看，统计数据显示，A股共有47 ...

长江商报消息 突然之间，河化股份（000953.SZ）股票涨停了，是否有异常？ 在股票涨停的当晚，河化股份发布公告称，公司收到控股股东宁波银亿控股有限公司（简称"银亿控 股"）的通知，其正在筹划股权转让相关事宜，该事项可能导致公司控股股东及实际控制人发生变更。 公司股票停牌自7月31日起停牌。 资本似乎不看好河化股份。2025年一季度末，公司前十大股东中无一家基金公司。 时隔9年面临再易主 河化股份面临再度易主。 根据公告，近日，河化股份收到控股股东银亿控股的通知，其正在筹划股权转让相关事宜，该事项可能 导致公司控股股东及实际控制人发生变更。 公告称，目前，各方尚未签署相关正式交易协议，拟就相关事项进行进一步论证和磋商，具体情况以各 方签订的相关正式交易协议为准。 因为上述事项，自7月31日开市起，河化股份的股票停牌，预计停牌时间不超过2个交易日。 此事在股吧引发热议。因为，在宣布停牌前的7月30日，河化股份的股票突然涨停。有声音质疑公司走 漏了风声。 河化股份的现任实际控制人是熊续强，其曾是宁波首富，因为激进扩张，早已成"首负"。2016年，熊续 强通过银亿控股拿下了河化股份控制权。 河化股份原本主营尿素等 ...

Industry News - The State Council held a press conference announcing that starting from January 1, 2022, eligible infants can receive childcare subsidies, with a preliminary budget of approximately 90 billion yuan for this year [6] - A national teleconference on the prevention and control of the Chikungunya virus was held, emphasizing the need for environmental sanitation and effective mosquito control measures [6] - The Chinese medicine industry will implement labeling regulations for medicinal herbs starting August 1, 2023, requiring labels to include expiration dates [7] - The China Coking Industry Association held a market analysis meeting, where representatives agreed to raise coking prices by 50 to 75 yuan per ton starting July 31 [7] - A successful launch of low-orbit satellite internet satellites was conducted using the Long March 8 rocket, marking advancements in automated launch technology [8] Company News - Upwind New Materials announced a suspension of trading due to abnormal stock price fluctuations [3] - CATL reported a net profit of 30.5 billion yuan for the first half of the year, a year-on-year increase of 33.02%, and plans to distribute a cash dividend of 10.07 yuan per share [9] - Vanke A announced that Shenzhen Metro Group will provide a loan of up to 869 million yuan to the company [9] - XGIMI Technology projected a net profit increase of 2062% year-on-year for the first half of the year [9] - Yonghui Supermarket plans to raise no more than 3.992 billion yuan through a private placement for store upgrades [9] - Yangtze Power announced plans to invest approximately 26.6 billion yuan in the construction of the Gezhouba shipping capacity expansion project [9] - Digital Certification announced that its controlling shareholder intends to transfer shares without compensation, changing the controlling shareholder to Beijing Data Group [9] - Chip products from Shanghai Lisan are undergoing optimization, with no revenue generated yet [9] - Zhongwang Software is facing a copyright infringement lawsuit from Autodesk in a U.S. court [9] - Chipsea Technology is planning to issue H-shares and list on the Hong Kong Stock Exchange [9] - Sunshine Dairy announced that its controlling shareholder sold a total of 1.1452 million shares in the past two days [9]

Group 1 - The core point of the news is that Hehua Co., Ltd. is planning a potential share transfer that may lead to a change in its controlling shareholder and actual controller, as notified by its major shareholder, Ningbo Yinyi Holdings Co., Ltd. [1] - The company has announced a temporary suspension of its stock trading starting from July 31, due to the uncertainty surrounding the share transfer, with an expected suspension period of no more than two trading days [3] - Hehua Co., Ltd. is also participating in the establishment of a venture capital fund with a total initial subscription of 11 million yuan, where the company will contribute 5 million yuan, accounting for 45.45% of the total [4] Group 2 - Hehua Co., Ltd. primarily engages in the research, production, and sales of pharmaceutical intermediates, as well as the commissioned processing and sales of urea [5] - On July 30, the company's stock price experienced a significant increase, reaching a closing price of 8.02 yuan per share, with a total market capitalization of 2.9 billion yuan [5][6]

Group 1 - Lideman is planning a major asset restructuring by acquiring up to 70% of Beijing Xiansheng Xiangrui Biological Products Co., Ltd. This acquisition will grant Lideman control over the target company, which will become a subsidiary [1][2] - The target company specializes in in vitro diagnostic reagents and human vaccines, with products primarily used for tuberculosis screening, diagnosis, treatment, and innovative vaccine development. The acquisition will enhance Lideman's IVD business segment and overall competitiveness [2] Group 2 - Hehua Co. and Sanchao New Materials are planning control changes, leading to a suspension of their stocks starting July 31, 2025, for up to two trading days [3] - Changjiang Electric Power has approved an investment of approximately 26.6 billion yuan for the construction of the Gezhouba shipping capacity expansion project, with funding sourced from its own funds [4] Group 3 - Contemporary Amperex Technology Co., Ltd. (CATL) reported a 7.27% increase in revenue to 178.886 billion yuan and a 33.33% increase in net profit to 30.485 billion yuan for the first half of 2025. The company plans to distribute a cash dividend of 10.07 yuan per 10 shares [5] - Dingtong Technology reported a 73.51% increase in revenue to 0.785 billion yuan and a 134.06% increase in net profit to 0.115 billion yuan for the first half of 2025 [6] - XGIMI Technology expects a net profit of 88.662 million yuan for the first half of 2025, a significant increase of 2062.33% compared to the previous year [7] Group 4 - Jinchengzi is planning to acquire 55% of Changchun Samit Optoelectronics Technology Co., Ltd. through a combination of stock issuance and cash payment, with the stock suspension starting July 31, 2025, for up to 10 trading days [8] - Digital Certification is undergoing a change in its controlling shareholder due to the establishment of Beijing Data Group, which will involve the transfer of shares from its current controlling shareholder [9][10]

Core Viewpoint - Hehua Co., Ltd. (河化股份) announced a suspension of its stock trading due to a planned change in control, with the suspension expected to last no more than two trading days [2][4]. Group 1: Company Background - Hehua Co., Ltd. primarily engages in the research, production, and sales of pharmaceutical intermediates, as well as the commissioned processing and sales of urea [5]. - The company’s subsidiary, Nansong Pharmaceutical, specializes in the development and production of pharmaceutical intermediates, with products sold domestically and internationally, including to countries like India and Finland [5]. - Hehua Co., Ltd. has undergone two changes in actual control since its establishment in 1993, with the current controlling shareholder being Ningbo Yinyi Holdings Co., Ltd. (银亿控股) since 2016 [5]. Group 2: Recent Developments - Ningbo Yinyi Holdings is currently planning a share transfer that may lead to a change in the controlling shareholder and actual controller of Hehua Co., Ltd. [4]. - The company reported a revenue of 40.83 million yuan in Q1, a year-on-year decrease of 34.05%, but achieved a net profit of 1.36 million yuan, marking a turnaround from losses [5]. - Hehua Co., Ltd. has faced operational challenges, including a significant decline in performance after the acquisition of Nansong Pharmaceutical, which was intended to pivot the business towards fine chemical production [8]. Group 3: Financial and Market Performance - Hehua Co., Ltd. has seen its stock price increase by over 40% this year, with a notable surge on July 30, when the stock hit the daily limit [9]. - The company is focusing on enhancing its core business and expanding market reach to identify new profit growth points [9].

Group 1 - The company announced that its controlling shareholder, Ningbo Yinyi Holdings Co., Ltd., is planning a share transfer that may lead to a change in the controlling shareholder and actual controller [2] - The company's stock was suspended from trading starting July 31, with an expected suspension period of no more than two trading days [2] - On July 30, the company's stock price hit the daily limit, closing at 8.02 yuan per share, with a market capitalization exceeding 2.9 billion yuan [2] Group 2 - In 2024, the company achieved operating revenue of 212 million yuan, a year-on-year increase of 12.81%, and a net profit of 79.25 million yuan, compared to a net loss of 11.56 million yuan in 2023 [2] - The strong performance was attributed to robust growth in the pharmaceutical intermediates business and steady improvement in the urea business, although challenges remain in cost control and market expansion [2] - For 2025, the company plans to expand its existing product supply chain, enhance management efficiency, increase R&D investment, and support the strategic transformation of its main business, Nansong Pharmaceutical [3] Group 3 - In Q1 2025, the company reported operating revenue of 40.83 million yuan, a year-on-year decline of 34.05%, and a net profit of 1.36 million yuan, compared to a net loss of 116,000 yuan in the same period last year [3] - The company aims to overcome challenges such as significant fluctuations in the urea market and the diminishing brand effect of its urea products [3]